Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148381 | 0.94 | MAP4K4 (0.54) | PDE4BMAP4K4PDE4APDE4CPDE4D | |
| SCHEMBL17050363 | 0.88 | NR1H4 (0.48) | NR1H4KDM2BKDM4CPDE4BMAP4K4 | |
| SCHEMBL28034346 | 0.86 | PDE4B (0.53) | NR1H4PDE4BMAP4K4PDE4APDE4C | |
| SCHEMBL27195879 | 0.85 | RBP4 (0.47) | KDM2BKDM4CPDE4BMRGPRX4 | |
| SCHEMBL30863550 | 0.85 | RBP4 (0.47) | KDM2BKDM4CPDE4BMRGPRX4 | |
| SCHEMBL1031663 | 0.84 | CA12 (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29670247 | 0.84 | TSHR (0.66) | PDE4BPDE4APDE4CPDE4DMRGPRX4 | |
| SCHEMBL10180471 | 0.84 | ALDH1A1 (0.54) | MRGPRX4 | |
| SCHEMBL30575456 | 0.84 | CA12 (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15596058 | 0.84 | TSHR (0.66) | PDE4BPDE4APDE4CPDE4DMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | NR1H4 405/4885KDM2B 3056/4885KDM4C 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.